BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.

Develop a holistic GLP-1 strategy An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use